Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017:88:201-205.

Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy

Giovanni Corso, Chiara Maria Grana, Laura Gilardi, Silvia Melania Baio, Daniela De Lorenzo, Patrick Maisonneuve, Nicole Rotmensz, Bettina Ballardini, Germana Lissidini, Silvia Ratini, Fabio D Bassi, Paolo Veronesi, Viviana Galimberti
  • PMID: 28874624

Feasibility of lymphoscintigraphy for sentinel node identification after neo-adjuvant therapy

Giovanni Corso et al. Ann Ital Chir. 2017.

Abstract
in English, Italian

Aim: To assess the sentinel-node identification rate at lymphoscintigraphy and its technical feasibility after neo-adjuvant treatments.

Material of study: Between 2000 and 2013, 444 consecutive patients affected by primary locally advanced breast cancer were enrolled in this study. All individuals were candidate for neo-adjuvant treatments and for lymphoscintigraphy before surgery.

Results: The median age was 44 years at onset; almost one sentinel node was identified during lymphoscintigraphy in 430 cases. The detection rate at lymphoscintigraphy was 96.9% (95% CI, 94.8-98.1%). Considering the correlation between specific treatments and sentinel node identification rate, we verified that the detection rate did not vary significantly (p=0.53) according to the type of neo-adjuvant therapies administered to the patients.

Conclusions: Our results demonstrated that lymphoscintigraphy for sentinel node identification is a safe and feasible procedure after neo-adjuvant therapies, independently of treatment types.

Key words: Breast Cancer, Neo-Adjuvant Treatment, Sentinel lymphnode biopsy, Lymphoscintigraphy.

Lo scopo dello studio è quello di valutare la fattibilità della linfoscintigrafia dopo trattamento neoadiuvante nelle pazienti affette da carcinoma mammario localmente avanzato. Sono state selezionate 444 pazienti dal 2000 al 2013 con neoplasia mammaria e candidate al trattamento neoadiuvante e alla linfoscintigrafia prima dell’intervento chirurgico. L’età media era di 44 anni alla diagnosi. In 430 casi almeno un linfonodo sentinella era stato identificato alla linfoscintigrafia. L’identification rate complessivo era del 96.9% (95% CI, 94.8-98.1%). Non abbiamo notato una correlazione statistica tra l’identification rate e il tipo di trattamento neoadiuvante eseguito (p=0.53). I nostri risultati hanno dimostrato che la linfoscintigrafia per l’identificazione del linfonodo sentinella è una procedura fattibile dopo trattamento neoadiuvante, indipendentemente dal tipo di farmaco utilizzato.

PubMed Disclaimer

MeSH terms

LinkOut - more resources